<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01088347</url>
  </required_header>
  <id_info>
    <org_study_id>24-11-2009 (versions 2.0)</org_study_id>
    <secondary_id>2009-015941-22</secondary_id>
    <nct_id>NCT01088347</nct_id>
  </id_info>
  <brief_title>Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer</brief_title>
  <official_title>A Phase 1b/2 Study With the Agonistic TRAIL-R1 Antibody, Mapatumumab, in Combination With Cisplatin and Radiotherapy as a First Line Therapy in Patients With Advanced Cervical Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Human Genome Sciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemoradiotherapy has become the standard of care for women with locally advanced cervical&#xD;
      cancer. The available data support a 30 to 50% reduction in the risk of death from cervical&#xD;
      cancer for women with locally advanced disease undergoing radiotherapy (RT) and concomitant&#xD;
      cisplatin-based chemotherapy compared to RT alone. Despite the fact that this is currently&#xD;
      the best treatment of locally advanced cervical cancer, 5-year overall survival is still only&#xD;
      52%.&#xD;
&#xD;
      The fully human, agonist monoclonal antibody mapatumumab binds to the Tumor necrosis&#xD;
      factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1, DR4) and induces cytotoxicity&#xD;
      in multiple tumor cell lines in vitro and in vivo. In multiple phase I and phase II studies,&#xD;
      mapatumumab appeared to be safe both as single agent and in combination with chemotherapy,&#xD;
      including cisplatin.&#xD;
&#xD;
      In cervical cancer cell lines, mapatumumab induced apoptosis in 51% of the cells. Mapatumumab&#xD;
      in combination with irradiation increased apoptosis to 83%.&#xD;
&#xD;
      In this phase 1b/2 study, the investigators will evaluate the safety, tolerability and&#xD;
      efficacy of mapatumumab in combination with cisplatin and radiotherapy in patients with&#xD;
      locally advanced cervical cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b: safety and tolerability of mapatumumab in combination with cisplatin and radiotherapy Phase 2: efficacy of mapatumumab in combination with cisplatin and radiotherapy</measure>
    <time_frame>5 months</time_frame>
    <description>Phase 2: pathological complete response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival, overall survival</measure>
    <time_frame>From enrollment until recurrence of disease, from enrollment until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apoptotic pathway biomarkers, PK parameters</measure>
    <time_frame>During the study, until 5 months after enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Advanced Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Advanced cervical cancer patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mapatumumab</intervention_name>
    <description>Mapatumumab (10 or 30 mg/kg) intravenously on days 1, 22, and 45. In phase 2 the MTD established in phase 1 will be used.</description>
    <arm_group_label>Advanced cervical cancer patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Cisplatin 40 mg/m2 intravenously on days 8, 15, 22, 29, 36, and 45</description>
    <arm_group_label>Advanced cervical cancer patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>Radiotherapy: a total dose of 45 Gy will be given in fractions of 1.8 Gy, five fractions per week (days 8-12, 15-19, 22-26, 29-33, and 36-40), by external beam irradiation by photon beam of at least 6 MV. After completing the five weeks of external beam irradiation, evaluation will take place to determine whether the boost can be given by brachytherapy. If brachytherapy is not feasible, the boost will be given by external beam irradiation to a total dose of 70.2 Gy in fractions of 1.8 Gy.</description>
    <arm_group_label>Advanced cervical cancer patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically or cytologically confirmed stage IB2, IIA2, IIB, III, and&#xD;
             IVA cervical cancer, according to the FIGO classification&#xD;
&#xD;
          2. Adequate bone marrow, renal and liver function:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1.5 x 109 /L.&#xD;
&#xD;
               -  Platelet count ≥ 100 x 109 /L.&#xD;
&#xD;
               -  Serum creatinine level ≤ 1.5 x upper limit of normal (ULN).&#xD;
&#xD;
               -  Total bilirubin &lt; 1.25 x ULN.&#xD;
&#xD;
               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN.&#xD;
&#xD;
          3. Performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) Scale.&#xD;
&#xD;
          4. Age 18 years or older.&#xD;
&#xD;
          5. Life expectancy of ≥ 12 weeks.&#xD;
&#xD;
          6. Have the ability to understand the requirements of the study, provide written informed&#xD;
             consent (including consent for the use and disclosure of research-related health&#xD;
             information), and comply with the study and follow-up procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any co-morbid condition that in the judgment of the investigator renders the subject&#xD;
             at high risk of treatment complications or reduces the possibility of assessing&#xD;
             clinical effect.&#xD;
&#xD;
          2. Cytotoxic agent, hormonal therapy, or radiation therapy within 3 weeks (6 weeks for&#xD;
             nitrosoureas or mitomycin-C) prior to day 1, cycle 1; investigational agent within 4&#xD;
             weeks prior to day 1, cycle 1.&#xD;
&#xD;
          3. Need for concomitant anticancer therapy (surgery, radiation therapy, chemotherapy,&#xD;
             immunotherapy, radiofrequency ablation) or other investigational agents during the&#xD;
             study treatment period.&#xD;
&#xD;
          4. Major surgery within 4 weeks before enrollment; minor surgery (except for insertion of&#xD;
             vascular access device) within 2 weeks before enrollment; or not yet recovered from&#xD;
             the effects of the surgery.&#xD;
&#xD;
          5. Systemic steroids within 1 week before enrollment except steroids used as part of an&#xD;
             antiemetic regimen or maintenance-dose steroids for non-cancerous disease.&#xD;
&#xD;
          6. History of any infection requiring hospitalization or antibiotics within 2 weeks&#xD;
             before enrollment.&#xD;
&#xD;
          7. Known brain or spinal cord metastases unless adequately treated (surgery or&#xD;
             radiotherapy) with no evidence of progression and neurologically stable off&#xD;
             anticonvulsants and steroids.&#xD;
&#xD;
          8. Known human immunodeficiency virus infection.&#xD;
&#xD;
          9. Unstable angina, myocardial infarction, cerebrovascular accident, &gt; Class II&#xD;
             congestive heart failure according to the New York Heart Association Classification&#xD;
             for Congestive Heart Failure within 6 months before enrollment.&#xD;
&#xD;
         10. Pregnant female or nursing mother.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>An KL Reyners, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Maduro JH, de Vries EG, Meersma GJ, Hougardy BM, van der Zee AG, de Jong S. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis. Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):543-52. doi: 10.1016/j.ijrobp.2008.06.1902.</citation>
    <PMID>18793956</PMID>
  </reference>
  <reference>
    <citation>Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, Eskens FA, Loos WJ, de Vries EG, Sleijfer S. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res. 2009 Sep 1;15(17):5584-90. doi: 10.1158/1078-0432.CCR-09-0996. Epub 2009 Aug 18. Erratum in: Clin Cancer Res. 2009 Nov 1;15(21):6744.</citation>
    <PMID>19690193</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>March 10, 2010</study_first_submitted>
  <study_first_submitted_qc>March 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2010</study_first_posted>
  <last_update_submitted>April 21, 2015</last_update_submitted>
  <last_update_submitted_qc>April 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>A.K.L. Reyners</investigator_full_name>
    <investigator_title>Medical Oncologist</investigator_title>
  </responsible_party>
  <keyword>TRAIL</keyword>
  <keyword>TRM1</keyword>
  <keyword>advanced cervical cancer</keyword>
  <keyword>mapatumumab</keyword>
  <keyword>Uterine cervical neoplasm</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mapatumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

